Is Increasing Drug Solubility The Answer To Improving Topical Eye Drug Delivery?
Improving the Delivery of Topical Ocular Drops
Using semifluorinated alkanes to transform poorly soluble drugs into effective therapeutics.
BY BERNHARD GÜNTHER, CEO, NOVALIQ GMBH
Novaliq GmbH, based in Heidelberg, Germany, is a drug delivery company that is developing a superior generation of ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of eye drops or an eye spray.
Since its establishment in 2007, Novaliq has obtained four rounds of funding totalling €13.2 million from its major shareholder, Dievini Hopp Biotech Holding (a venture capital company focusing on biopharmaceutical companies in Europe). This funding is anticipated to support the company until 2015.
[…]
